International Journal of Clinical Medicine

Volume 4, Issue 5 (May 2013)

ISSN Print: 2158-284X   ISSN Online: 2158-2882

Google-based Impact Factor: 0.52  Citations  h5-index & Ranking

Topical CuradermBEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes

HTML  XML Download Download as PDF (Size: 864KB)  PP. 233-238  
DOI: 10.4236/ijcm.2013.45041    6,012 Downloads   10,013 Views  Citations
Author(s)

ABSTRACT

Approximately 5 to 10 percent of all skin cancers occur in the periocular region. Basal cell carcinoma is the most frequent malignant periocular tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Nonmelanoma skin tumors at the periocular area often cause disfigurement with destruction of soft conjunctival tissue. Many therapeutic methods have been recommended to combat the morbidity and mortality associated with these lesions. Excisions with frozen-section control or Mohs micrographic surgery are regarded as the gold-standard treatments for periocular basal cell and squamous cell carcinomas. However, these treatment modalities have various limitations and reconstruction surgery is often associated with these treatment options. The chemotherapeutic agents solasodine rhamnosides in a cream formulation CuradermBEC5 are specific, effective and safe treatments for nonmelanoma skin cancers with excellent cosmesis. The antineoplastic mode of action is by apoptosis. In this review it is shown that CuradermBEC5 also treats periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no reconstructive surgery is required.

Share and Cite:

B. Cham, "Topical CuradermBEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes," International Journal of Clinical Medicine, Vol. 4 No. 5, 2013, pp. 233-238. doi: 10.4236/ijcm.2013.45041.

Cited by

[1] The Pharmacology of Curaderm in the Treatment of Basal Cell Carcinoma
Clin Med Rev Case Rep, 2022
[2] Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute Survival
2020
[3] Curaderm, the Long-Awaited Breakthrough for Basal Cell Carcinoma
2020
[4] First in Man Topical Treatment of Melanoma with Solasodine Glycosides in a Formulation Curaderm: A Case Report
2020
[5] Outside the Box Cancer Therapies: Alternative Therapies That Treat and Prevent Cancer
2019
[6] “Dr. Stengler and Dr. Anderson expertly provide clear, practical tools that can possibly save your life or someone close to you. By harnessing the healing power …
2018
[7] Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies
2017
[8] A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity. Relevance to BEC and Solamargine, Example of a …
2015
[9] A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical …
2015
[10] Therapeutic Potential of Steroidal Alkaloids in Cancer and Other Diseases
Medicinal research reviews, 2015
[11] A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation Curaderm BEC5
Journal of Cancer Treatment and Research, 2015
[12] Treatment of Skin Cancer with a Selective Apoptotic-Inducing CuradermBEC5 Topical Cream Containing Solasodine Rhamnosides
International Journal of Clinical Medicine, 2015
[13] Treatment of Non Melanoma Skin Cancers: An Intra-Comparison Study of CuradermBEC5 and Various Established Modalities
Journal of Cancer Therapy, 2015
[14] Topical Cream Curadermbec5 Treats a Recalcitrant Basal Cell Carcinoma
2015
[15] AGROBACTERIUM RHIZOGENES-MEDIATED HAIRY ROOT OF APPLE OF SODOM (SOLANUM MAMMOSUM L.) FOR OPTIMIZED PRODUCTION OF …
2015
[16] A standardized plant extract containing a target compound is acceptable as a potent therapeutic entity: Relevance to BEC and solamargine, a topical clinical …
2015
[17] A review of solasodine rhamnosides therapy for in-situ squamous cell carcinoma on the penis
British Journal of Medicine and Medical Research, 2014
[18] A review of solasodine rhamnosides therapy for in-situ squamous cell carcinoma on the penis.
British Journal of Medicine and Medical Research, 2014

Journals Menu
Follow SCIRP
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.